A citation-based method for searching scientific literature

Wolfgang Wick, Christian Hartmann, Corinna Engel, Mandy Stoffels, Jörg Felsberg, Florian Stockhammer, Michael C Sabel, Susanne Koeppen, Ralf Ketter, Richard Meyermann, Marion Rapp, Christof Meisner, Rolf D Kortmann, Torsten Pietsch, Otmar D Wiestler, Ulrike Ernemann, Michael Bamberg, Guido Reifenberger, Andreas von Deimling, Michael Weller. J Clin Oncol 2009
Times Cited: 552







List of co-cited articles
589 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
55

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
Martin J van den Bent, Alba A Brandes, Martin J B Taphoorn, Johan M Kros, Mathilde C M Kouwenhoven, Jean-Yves Delattre, Hans J J A Bernsen, Marc Frenay, Cees C Tijssen, Wolfgang Grisold,[...]. J Clin Oncol 2013
661
40

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Gregory Cairncross, Meihua Wang, Edward Shaw, Robert Jenkins, David Brachman, Jan Buckner, Karen Fink, Luis Souhami, Normand Laperriere, Walter Curran,[...]. J Clin Oncol 2013
619
37

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
35

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
Jan C Buckner, Edward G Shaw, Stephanie L Pugh, Arnab Chakravarti, Mark R Gilbert, Geoffrey R Barger, Stephen Coons, Peter Ricci, Dennis Bullard, Paul D Brown,[...]. N Engl J Med 2016
461
33

MGMT gene silencing and benefit from temozolomide in glioblastoma.
Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani,[...]. N Engl J Med 2005
31

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, Andreas von Deimling, Thierry Gorlia, Khê Hoang-Xuan, Alba A Brandes, Guy Kantor, Martin J B Taphoorn, Mohamed Ben Hassel,[...]. Lancet Oncol 2016
225
29

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
Martin J van den Bent, Brigitta Baumert, Sara C Erridge, Michael A Vogelbaum, Anna K Nowak, Marc Sanson, Alba Ariela Brandes, Paul M Clement, Jean Francais Baurain, Warren P Mason,[...]. Lancet 2017
165
24

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
Daniel J Brat, Roel G W Verhaak, Kenneth D Aldape, W K Alfred Yung, Sofie R Salama, Lee A D Cooper, Esther Rheinbay, C Ryan Miller, Mark Vitucci, Olena Morozova,[...]. N Engl J Med 2015
23

Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.
Wolfgang Wick, Patrick Roth, Christian Hartmann, Peter Hau, Makoto Nakamura, Florian Stockhammer, Michael C Sabel, Antje Wick, Susanne Koeppen, Ralf Ketter,[...]. Neuro Oncol 2016
106
22

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
21

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.
Michael Weller, Martin van den Bent, Jörg C Tonn, Roger Stupp, Matthias Preusser, Elizabeth Cohen-Jonathan-Moyal, Roger Henriksson, Emilie Le Rhun, Carmen Balana, Olivier Chinot,[...]. Lancet Oncol 2017
484
20

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Roger Stupp, Monika E Hegi, Warren P Mason, Martin J van den Bent, Martin J B Taphoorn, Robert C Janzer, Samuel K Ludwin, Anouk Allgeier, Barbara Fisher, Karl Belanger,[...]. Lancet Oncol 2009
19

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
Jeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Hugues Sicotte, Melike Pekmezci, Terri Rice, Matt L Kosel, Ivan V Smirnov,[...]. N Engl J Med 2015
990
17

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.
M J van den Bent, D Afra, O de Witte, M Ben Hassel, S Schraub, K Hoang-Xuan, P-O Malmström, L Collette, M Piérart, R Mirimanoff,[...]. Lancet 2005
562
16

The 2007 WHO classification of tumours of the central nervous system.
David N Louis, Hiroko Ohgaki, Otmar D Wiestler, Webster K Cavenee, Peter C Burger, Anne Jouvet, Bernd W Scheithauer, Paul Kleihues. Acta Neuropathol 2007
15

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
Gregory Cairncross, Brian Berkey, Edward Shaw, Robert Jenkins, Bernd Scheithauer, David Brachman, Jan Buckner, Karen Fink, Luis Souhami, Normand Laperierre,[...]. J Clin Oncol 2006
513
14

Mutational landscape and clonal architecture in grade II and III gliomas.
Hiromichi Suzuki, Kosuke Aoki, Kenichi Chiba, Yusuke Sato, Yusuke Shiozawa, Yuichi Shiraishi, Teppei Shimamura, Atsushi Niida, Kazuya Motomura, Fumiharu Ohka,[...]. Nat Genet 2015
454
14

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Patrick Y Wen, David R Macdonald, David A Reardon, Timothy F Cloughesy, A Gregory Sorensen, Evanthia Galanis, John Degroot, Wolfgang Wick, Mark R Gilbert, Andrew B Lassman,[...]. J Clin Oncol 2010
14

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Wolfgang Wick, Michael Platten, Christoph Meisner, Jörg Felsberg, Ghazaleh Tabatabai, Matthias Simon, Guido Nikkhah, Kirsten Papsdorf, Joachim P Steinbach, Michael Sabel,[...]. Lancet Oncol 2012
671
14

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
Andrew B Lassman, Fabio M Iwamoto, Timothy F Cloughesy, Kenneth D Aldape, Andreana L Rivera, April F Eichler, David N Louis, Nina A Paleologos, Barbara J Fisher, Lynn S Ashby,[...]. Neuro Oncol 2011
105
12

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Annika Malmström, Bjørn Henning Grønberg, Christine Marosi, Roger Stupp, Didier Frappaz, Henrik Schultz, Ufuk Abacioglu, Björn Tavelin, Benoit Lhermitte, Monika E Hegi,[...]. Lancet Oncol 2012
693
12

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Marc Sanson, Yannick Marie, Sophie Paris, Ahmed Idbaih, Julien Laffaire, François Ducray, Soufiane El Hallani, Blandine Boisselier, Karima Mokhtari, Khe Hoang-Xuan,[...]. J Clin Oncol 2009
696
12

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
12

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
Martin J van den Bent, Hendrikus J Dubbink, Marc Sanson, Cathleen R van der Lee-Haarloo, Monika Hegi, Judith W M Jeuken, Ahmed Ibdaih, Alba A Brandes, Martin J B Taphoorn, Marc Frenay,[...]. J Clin Oncol 2009
187
11

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
Martin J van den Bent, Antoine F Carpentier, Alba A Brandes, Marc Sanson, Martin J B Taphoorn, Hans J J A Bernsen, Marc Frenay, Cees C Tijssen, Wolfgang Grisold, Laslo Sipos,[...]. J Clin Oncol 2006
532
11

Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.
Barbara J Fisher, Chen Hu, David R Macdonald, Glenn J Lesser, Stephen W Coons, David G Brachman, Samuel Ryu, Maria Werner-Wasik, Jean-Paul Bahary, Junfeng Liu,[...]. Int J Radiat Oncol Biol Phys 2015
88
12

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
J Gregory Cairncross, Meihua Wang, Robert B Jenkins, Edward G Shaw, Caterina Giannini, David G Brachman, Jan C Buckner, Karen L Fink, Luis Souhami, Normand J Laperriere,[...]. J Clin Oncol 2014
255
11

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
James R Perry, Normand Laperriere, Christopher J O'Callaghan, Alba A Brandes, Johan Menten, Claire Phillips, Michael Fay, Ryo Nishikawa, J Gregory Cairncross, Wilson Roa,[...]. N Engl J Med 2017
392
11

A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.
A B Karim, B Maat, R Hatlevoll, J Menten, E H Rutten, D G Thomas, F Mascarenhas, J C Horiot, L M Parvinen, M van Reijn,[...]. Int J Radiat Oncol Biol Phys 1996
440
11


Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Olivier L Chinot, Wolfgang Wick, Warren Mason, Roger Henriksson, Frank Saran, Ryo Nishikawa, Antoine F Carpentier, Khe Hoang-Xuan, Petr Kavan, Dana Cernea,[...]. N Engl J Med 2014
10

Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.
Linda Douw, Martin Klein, Selene Saa Fagel, Josje van den Heuvel, Martin Jb Taphoorn, Neil K Aaronson, Tjeerd J Postma, W Peter Vandertop, Jacob J Mooij, Rudolf H Boerman,[...]. Lancet Neurol 2009
392
10

Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.
Edward G Shaw, Meihua Wang, Stephen W Coons, David G Brachman, Jan C Buckner, Keith J Stelzer, Geoffrey R Barger, Paul D Brown, Mark R Gilbert, Minesh P Mehta. J Clin Oncol 2012
192
10

cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
Daniel J Brat, Kenneth Aldape, Howard Colman, Eric C Holland, David N Louis, Robert B Jenkins, B K Kleinschmidt-DeMasters, Arie Perry, Guido Reifenberger, Roger Stupp,[...]. Acta Neuropathol 2018
297
10

A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Mark R Gilbert, James J Dignam, Terri S Armstrong, Jeffrey S Wefel, Deborah T Blumenthal, Michael A Vogelbaum, Howard Colman, Arnab Chakravarti, Stephanie Pugh, Minhee Won,[...]. N Engl J Med 2014
9

Surgical resection versus watchful waiting in low-grade gliomas.
A S Jakola, A J Skjulsvik, K S Myrmel, K Sjåvik, G Unsgård, S H Torp, K Aaberg, T Berg, H Y Dai, K Johnsen,[...]. Ann Oncol 2017
115
9

Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.
Susan Chang, Peixin Zhang, J Gregory Cairncross, Mark R Gilbert, Jean-Paul Bahary, Carol A Dolinskas, Arnab Chakravarti, Kenneth D Aldape, Erica H Bell, David Schiff,[...]. Neuro Oncol 2017
36
25

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Christian Hartmann, Bettina Hentschel, Wolfgang Wick, David Capper, Jörg Felsberg, Matthias Simon, Manfred Westphal, Gabriele Schackert, Richard Meyermann, Torsten Pietsch,[...]. Acta Neuropathol 2010
504
9

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Roger Stupp, Sophie Taillibert, Andrew Kanner, William Read, David Steinberg, Benoit Lhermitte, Steven Toms, Ahmed Idbaih, Manmeet S. Ahluwalia, Karen Fink,[...]. JAMA 2017
656
9

CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014.
Quinn T Ostrom, Haley Gittleman, Peter Liao, Toni Vecchione-Koval, Yingli Wolinsky, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2017
769
9

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.
Quinn T Ostrom, Haley Gittleman, Jordonna Fulop, Max Liu, Rachel Blanda, Courtney Kromer, Yingli Wolinsky, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2015
9

Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Erica H Bell, Peixin Zhang, Barbara J Fisher, David R Macdonald, Joseph P McElroy, Glenn J Lesser, Jessica Fleming, Arup R Chakraborty, Ziyan Liu, Aline P Becker,[...]. JAMA Oncol 2018
73
12

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Mark R Gilbert, Meihua Wang, Kenneth D Aldape, Roger Stupp, Monika E Hegi, Kurt A Jaeckle, Terri S Armstrong, Jeffrey S Wefel, Minhee Won, Deborah T Blumenthal,[...]. J Clin Oncol 2013
530
8

Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.
David E Reuss, Annekathrin Kratz, Felix Sahm, David Capper, Daniel Schrimpf, Christian Koelsche, Volker Hovestadt, Melanie Bewerunge-Hudler, David T W Jones, Jens Schittenhelm,[...]. Acta Neuropathol 2015
161
8

Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial.
Edward G Shaw, Brian Berkey, Stephen W Coons, Dennis Bullard, David Brachman, Jan C Buckner, Keith J Stelzer, Geoffrey R Barger, Paul D Brown, Mark R Gilbert,[...]. J Neurosurg 2008
186
8

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
Takuya Watanabe, Sumihito Nobusawa, Paul Kleihues, Hiroko Ohgaki. Am J Pathol 2009
668
8

Prognostic factors for survival in adult patients with cerebral low-grade glioma.
Francesco Pignatti, Martin van den Bent, Desmond Curran, Channa Debruyne, Richard Sylvester, Patrick Therasse, Denes Afra, Philippe Cornu, Michel Bolla, Charles Vecht,[...]. J Clin Oncol 2002
564
8

Diffuse Infiltrating Oligodendroglioma and Astrocytoma.
Martin J van den Bent, Marion Smits, Johan M Kros, Susan M Chang. J Clin Oncol 2017
78
10

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Sevin Turcan, Daniel Rohle, Anuj Goenka, Logan A Walsh, Fang Fang, Emrullah Yilmaz, Carl Campos, Armida W M Fabius, Chao Lu, Patrick S Ward,[...]. Nature 2012
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.